市場調查報告書

BRAF激化酵素抑制劑的全球市場:藥物,各適應症,各流通管道,各地區的市場規模,佔有率,展望,機會分析,2020年∼2027年

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968783
出版日期 內容資訊 英文 158 Pages
商品交期: 2-3個工作天內
價格
BRAF激化酵素抑制劑的全球市場:藥物,各適應症,各流通管道,各地區的市場規模,佔有率,展望,機會分析,2020年∼2027年 BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年10月13日內容資訊: 英文 158 Pages
簡介

BRAF是一種激酶酶,有助於控制細胞生長和信號轉導,在黑色素瘤和大腸癌中可能以突變(改變)的形式存在。它可用於癌症治療,因為它可以通過阻止突變的BRAF激酶蛋白來阻止癌細胞的生長。

本報告提供全球BRAF激化酵素抑制劑市場調查,提供市場力學和法規,新型冠狀病毒感染疾病(COVID-19)疫情的影響,藥物,各適應症,各流通管道,各地區的分析,競爭情形和企業簡介等資訊。

目錄

第1章 調查目的與前提條件

第2章 市場概要

  • 報告概要
  • 市場定義和範圍
  • 摘要整理
  • 市場明細:各藥物
  • 市場明細:各適應症
  • 市場明細:各流通管道
  • 市場明細:各地區
  • 市場機會藍圖

第3章 市場力學,法規,趨勢分析

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 影響分析
  • 產品銷售
  • 主要的動向
  • 法規方案
  • PEST分析
  • 治療的演進
  • 開發平台分析
  • 償付方案

第4章 COVID-19的影響

  • 供給面和需求面分析
  • 整體影響
  • 研究開發的影響

第5章 市場分析:各藥物

  • 簡介
  • Vemurafenib
  • Dabrafenib
  • rifirafenibu
  • Encorafenib

第6章 市場分析:各適應症

  • 簡介
  • 轉移性黑色素瘤
  • 轉移性肺癌症
  • 其他

第7章 市場分析:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 市場分析:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第9章 競爭情形

  • 企業簡介
    • F. Hoffmann-La Roche AG
    • Novartis International AG
    • Pfizer, Inc.

第10章

目錄

Title:
BRAF Kinase Inhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib, and Encorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.

Market Dynamics

Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.

However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.

Key features of the study:

  • This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global BRAF kinase inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global BRAF Kinase Inhibitors Market, By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
  • Global BRAF Kinase Inhibitors Market, By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
  • Global BRAF Kinase Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global BRAF Kinase Inhibitors Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
      • By Drug:
    • Vemurafenib
    • Dabrafenib
    • Lifirafenib
    • Encorafenib
      • By Indication:
    • Metastatic Melanoma
    • Metastatic Lung Cancer
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • F. Hoffmann-La Roche AG*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis International AG
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Product Launches
  • Key Developments
  • Regulatory Scenario
  • PEST Analysis
  • Treatment Evolution
  • Pipeline Analysis
  • Reimbursement Scenario

4. Impact of COVID-19 on BRAF Kinase Inhibitors Market

  • Supply Side And Demand Side Analysis
  • Overall Impact
  • Impact on Research and Development

5. Global BRAF Kinase Inhibitors Market, By Drug, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Vemurafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Dabrafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Lifirafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Encorafenib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global BRAF Kinase Inhibitors Market, By Indication, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Metastatic Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Metastatic Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global BRAF Kinase Inhibitors Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Drug, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Company Profiles
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact